(SAN) Sanofi - Ratings and Ratios
Immunology, Oncology, Neurology, Vaccines, Rare Diseases
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.56% |
| Yield on Cost 5y | 5.64% |
| Yield CAGR 5y | 4.67% |
| Payout Consistency | 95.7% |
| Payout Ratio | 74.8% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 21.6% |
| Value at Risk 5%th | 32.6% |
| Relative Tail Risk | -8.50% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.12 |
| Alpha | -5.49 |
| CAGR/Max DD | 0.08 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.413 |
| Beta | -0.093 |
| Beta Downside | 0.017 |
| Drawdowns 3y | |
|---|---|
| Max DD | 26.17% |
| Mean DD | 9.66% |
| Median DD | 9.01% |
Description: SAN Sanofi September 25, 2025
Sanofi SA (NASDAQ: SAN) is a global, integrated healthcare company that discovers, develops, manufactures, and markets therapeutic solutions across immunology, rare diseases, neurology, oncology, and vaccines. Its vaccine portfolio spans pediatric (polio, pertussis, Hib), respiratory syncytial virus, hexavalent combination vaccines, influenza, meningitis, and travel/endemic vaccines such as hepatitis A, typhoid, yellow fever, and rabies.
The firm maintains an extensive partnership network to accelerate innovation: a licensing deal with Exscientia for up to 15 novel small-molecule candidates in oncology and immunology; collaborations with ABL Bio (alpha-synucleinopathies), Innate Pharma (NK-cell engagers), Blackstone Life Sciences (clinical development), IGM Biosciences (IgM antibodies), Kymera Therapeutics (IRAK4 degraders), Nurix Therapeutics (targeted protein degradation), Denali Therapeutics (systemic inflammatory diseases), Adagene (antibody therapeutics), Scribe Therapeutics (genome editing), and a co-promotion agreement with Provention Bio for teplizumab. A strategic alliance with Abu Dhabi’s Department of Health supports global vaccine development.
From a financial perspective, Sanofi generated €44.9 billion in revenue in 2023, with the vaccines segment contributing roughly 20 % of total sales and growing at a 6 % compound annual growth rate (CAGR) since 2020. R&D intensity remains high at ~17 % of revenue, reflecting a commitment to pipeline renewal amid a competitive biotech landscape. Key macro drivers include an aging global population, rising prevalence of chronic inflammatory diseases, and sustained demand for innovative immunotherapies and next-generation vaccines.
For a deeper quantitative assessment of SAN’s valuation and risk profile, the ValueRay platform offers a data-rich dashboard worth exploring.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (9.30b TTM) > 0 and > 6% of Revenue (6% = 2.76b TTM) |
| FCFTA 0.13 (>2.0%) and ΔFCFTA 5.39pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 4.22% (prev -42.56%; Δ 46.78pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 17.06b > Net Income 9.30b (YES >=105%, WARN >=100%) |
| Net Debt (11.00b) to EBITDA (12.23b) ratio: 0.90 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.06 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.23b) change vs 12m ago -1.52% (target <= -2.0% for YES) |
| Gross Margin 71.98% (prev 69.51%; Δ 2.47pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 35.85% (prev 32.35%; Δ 3.50pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 10.02 (EBITDA TTM 12.23b / Interest Expense TTM 945.0m) >= 6 (WARN >= 3) |
Altman Z'' 4.94
| (A) 0.01 = (Total Current Assets 34.04b - Total Current Liabilities 32.10b) / Total Assets 129.79b |
| (B) 0.53 = Retained Earnings (Balance) 68.19b / Total Assets 129.79b |
| (C) 0.07 = EBIT TTM 9.47b / Avg Total Assets 128.13b |
| (D) 2.51 = Book Value of Equity 141.27b / Total Liabilities 56.26b |
| Total Rating: 4.94 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 75.44
| 1. Piotroski 7.0pt |
| 2. FCF Yield 15.07% |
| 3. FCF Margin 37.47% |
| 4. Debt/Equity 0.24 |
| 5. Debt/Ebitda 0.90 |
| 6. ROIC - WACC (= 3.25)% |
| 7. RoE 12.61% |
| 8. Rev. Trend 11.94% |
| 9. EPS Trend 11.13% |
What is the price of SAN shares?
Over the past week, the price has changed by +1.07%, over one month by -2.16%, over three months by -0.36% and over the past year by -2.47%.
Is SAN a buy, sell or hold?
What are the forecasts/targets for the SAN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 106.3 | 23.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 90.7 | 5.6% |
SAN Fundamental Data Overview November 27, 2025
Market Cap EUR = 105.22b (105.22b EUR * 1.0 EUR.EUR)
P/E Trailing = 16.4866
P/E Forward = 10.1317
P/S = 2.2909
P/B = 1.4248
P/EG = 0.7564
Beta = 0.371
Revenue TTM = 45.93b EUR
EBIT TTM = 9.47b EUR
EBITDA TTM = 12.23b EUR
Long Term Debt = 11.70b EUR (from longTermDebt, last quarter)
Short Term Debt = 8.20b EUR (from shortLongTermDebt, last quarter)
Debt = 17.91b EUR (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 11.00b EUR (from netDebt column, last quarter)
Enterprise Value = 114.22b EUR (105.22b + Debt 17.91b - CCE 8.91b)
Interest Coverage Ratio = 10.02 (Ebit TTM 9.47b / Interest Expense TTM 945.0m)
FCF Yield = 15.07% (FCF TTM 17.21b / Enterprise Value 114.22b)
FCF Margin = 37.47% (FCF TTM 17.21b / Revenue TTM 45.93b)
Net Margin = 20.24% (Net Income TTM 9.30b / Revenue TTM 45.93b)
Gross Margin = 71.98% ((Revenue TTM 45.93b - Cost of Revenue TTM 12.87b) / Revenue TTM)
Gross Margin QoQ = 74.09% (prev 72.13%)
Tobins Q-Ratio = 0.88 (Enterprise Value 114.22b / Total Assets 129.79b)
Interest Expense / Debt = 1.27% (Interest Expense 227.0m / Debt 17.91b)
Taxrate = 19.38% (680.0m / 3.51b)
NOPAT = 7.63b (EBIT 9.47b * (1 - 19.38%))
Current Ratio = 1.06 (Total Current Assets 34.04b / Total Current Liabilities 32.10b)
Debt / Equity = 0.24 (Debt 17.91b / totalStockholderEquity, last quarter 73.26b)
Debt / EBITDA = 0.90 (Net Debt 11.00b / EBITDA 12.23b)
Debt / FCF = 0.64 (Net Debt 11.00b / FCF TTM 17.21b)
Total Stockholder Equity = 73.71b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.16% (Net Income 9.30b / Total Assets 129.79b)
RoE = 12.61% (Net Income TTM 9.30b / Total Stockholder Equity 73.71b)
RoCE = 11.09% (EBIT 9.47b / Capital Employed (Equity 73.71b + L.T.Debt 11.70b))
RoIC = 8.24% (NOPAT 7.63b / Invested Capital 92.60b)
WACC = 4.99% (E(105.22b)/V(123.13b) * Re(5.67%) + D(17.91b)/V(123.13b) * Rd(1.27%) * (1-Tc(0.19)))
Discount Rate = 5.67% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -81.65 | Cagr: -0.79%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈14.30b ; Y1≈17.65b ; Y5≈30.11b
Fair Price DCF = 421.6 (DCF Value 512.05b / Shares Outstanding 1.21b; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 11.13 | EPS CAGR: 22.01% | SUE: 1.43 | # QB: 1
Revenue Correlation: 11.94 | Revenue CAGR: 6.46% | SUE: 0.46 | # QB: 0